GLP-1 Market
LLY $1157.49 ▲ +1.3% NVO $37.53 ▼ -0.0% PFE $27.50 ▲ +0.3% VKTX $28.38 ▼ -3.1% KLRA $10.83 ▼ -0.1% GPCR $27.47 ▼ -0.4% RHHBY $52.55 ▲ +0.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AZ-3102

AZ-3102

Company
Azafaros B.V.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 7, 2026

Find a Clinical Trial Near Me

See recruiting studies for AZ-3102 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07054515

    A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

    Not yet reported Azafaros B.V. 147 participants Est. completion 2028-06-14 39 sites Stand-alone
    Other conditions: Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
    View official trial listing →
  • Recruiting NCT NCT07082725

    A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

    Not yet reported Azafaros B.V. 72 participants Est. completion 2028-06-14 34 sites Stand-alone
    Other conditions: Niemann-Pick Type C Disease
    View official trial listing →
  • Recruiting NCT NCT07399704

    A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

    Not yet reported Azafaros B.V. 21 participants Est. completion 2030-08-07 3 sites Stand-alone
    Other conditions: GM2 Gangliosidosis, Niemann-Pick Type C Disease
    View official trial listing →
  • Completed NCT NCT05758922

    Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

    Not yet reported Azafaros B.V. 13 participants Est. completion 2026-05-05 3 sites Stand-alone
    Other conditions: GM2 Gangliosidosis, Niemann-Pick Disease, Type C
    View official trial listing →
  • Active, not recruiting NCT NCT07082543

    A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

    Not yet reported Azafaros B.V. 75 participants Est. completion 2028-03-06 27 sites Stand-alone
    Other conditions: Gangliosidoses, GM2, Gangliosidosis, GM1
    View official trial listing →
  • Not yet recruiting NCT NCT07715084

    Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)

    Not yet reported Azafaros B.V. 20 participants Est. completion 2029-07 7 sites Stand-alone
    Other conditions: Gaucher Disease Type 3
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: AZ-3102, nizubaglustat

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.